Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development, and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer. Casdozokitug is a novel anti-IL-27 antibody being evaluated in two ongoing clinical studies. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the novel pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a novel PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor. It is also focused on developing YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.